Kymera Therapeutics' KT-621 shows promise as a first-in-class oral treatment for inflammatory diseases. Phase 1 data releases June 2. Read more here.

Organic light emitting diodes, or OLEDs, are a type of photoluminescence device that utilizes organic compounds to produce ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...